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The tradition of the Symposia of Jagiellonian Medi-
cal Research Centre is to present achievements of
Western and Eastern researchers in the field of
physiology and pharmacology of cardiovascular
system. The recent 9th Symposium on ÔPharmaco-
logy of Vascular WallÕ was honoured by participa-
tion in it of two Nobel Prize Laureates. Sir John Va-
ne (Nobel Prize 1982) was deeply engaged in di-
scoveries of ACE-inhibitors, prostacyclin and the
mode of action of aspirin. He gave his broad and
personal view on enzymes and mediators abiding
vascular wall and on their significance in health
and disease. Ferid Murad (Nobel Prize 1998) is
one of the discoverers of biological and pharmaco-
logical significance of nitric oxide (NO). He expo-
sed a link between NO and soluble guanylate cyc-
lase in the signal transduction. Stefan Ch‚opicki po-
inted out the pneumoprotective role of NO in en-
dotoxemia, while molecular mechanisms triggering
the release of ATP from erythrocytes were reported
by Randy Sprague. John C. McGiff, the Oversea
President of our International Jagiellonian Club, is
well known thanks of his studies on cytochrome
P 450-dependent pathway, the third pathway of
arachidonic acid metabolism. He focused his at-
tention on the dominant regulatory role of 20-hy-
droxyeicosatetraenoic acid (20-HETE) in preglome-
rular renal circulation. Mairead A. Carroll develo-
ped an idea on a balance between 20-HETE and
epoxyeicosatrienoic acids (EETs) in regulation of re-
nal microvessels. William B. Campbell and John
Quilley referred to EETs as to possible candidates
for endothelium-derived hyperpolarizing factor
(EDHF), that might be a major endothelial product
released by atherosclerotic blood vessels. New ide-
as on atherogenesis were reported by Chris Thie-
mermann, Angelo Sala and Marek Radomski with
respect to high density lipoproteins in vascular in-
flammation, transcellular biosynthesis of peptido-
leukotrienes, and a role of matrix metalloproteina-
ses in vascular wall. Helmut Sinzinger and Heikki
Vapaatalo presented clinically important methods
for detection of endothelial dysfunction in athero-
sclerosis, while Gautam Chaudhuri and Jean-Clau-
de Stoclet addressed the question of its correction
by either estrogens or wine polyphenols, respecti-
vely. Pharmacological correction of endothelial
dysfunction was portrayed in a series of lectures by
Ryszard Gryglewski, Andrzej Szczeklik and Tadeusz
Malinski. This particular cluster of lectures was
strongly devoted to the unexpected pleiotropic
mechanisms of action of statins. These hypochole-
sterolemic drugs known as inhibitors of hydroxy-
-glutaryl-CoA reductase have recently become bre-
cognised as thrombolytic agents which release en-
dothelial prostacyclin and  nitric oxide. Moreover,
they act also as antithrombotic agents through inhi-
bition of thrombinogenesis. Marek Naruszewicz ro-
unded up the pharmacological approach by pre-
senting his data on pleiotropic anti-atherosclerotic
action of anti-inflammatory drugs.
